In the media Archives - TMC

Services
TMC is a global pharma services company that delivers drug development solutions across the full product lifecycle — from early-phase clinical development to market access and drug commercialisation.

Our integrated pharma services and end-to-end support enable small to mid-sized biotech and pharma companies to retain control, maximise value and bring transformative therapies to patients faster.
Consulting
Clinical
Commercial
About Us
TMC is a global pharma services company supporting small to mid-sized biotech and pharma companies worldwide — across all stages of drug development.

Our experienced, senior specialists help you navigate clinical and regulatory complexity, accelerate drug development timelines and bring life-changing therapies to patients faster through expert, end-to-end support across clinical development, functional execution and drug commercialisation.
Our Leadership Team
Our Associates
Our ESG
Testimonials
Resources
News & Events
- News
- Events
Careers with TMC
- Join Our Team
- Join Our Network
Contact Us

Closing the gap between promise and reality for rare disease DCTs (International Clinical Trials, p.28)

By TMC|2026-05-26T13:35:02+01:0021 May 2026|In the media|0 Comments

TMC wins rare disease CRO of the year 2026 (Global Health & Pharma)

By TMC|2026-05-21T13:15:04+01:0013 May 2026|In the media|0 Comments

The diagnostic odyssey: how misdiagnosis and indication broadening can undermine rare disease clinical trials (Rare Revolution)

By TMC|2026-05-21T12:48:25+01:009 April 2026|In the media|0 Comments

Alpha-1 antitrypsin deficiency (AATD): navigating the drug-development pathway to successful clinical trial execution (EC Pulmonary and Respiratory Medicine)

By TMC|2026-05-21T13:10:54+01:003 February 2026|In the media|0 Comments

Alpha-1 antitrypsin deficiency (AATD): understanding the patient journey and burdens (EC Pulmonary and Respiratory Medicine)

By TMC|2026-05-21T13:10:59+01:0021 November 2025|In the media|0 Comments

Taking an inquirer-centric approach to rare disease medical information (Life Sciences Review)

By Marcelo Vaz, Vice President of Medical Services at [...]

By TMC|2026-05-21T13:11:29+01:0025 June 2025|In the media|0 Comments

The importance of incorporating decentralised clinical trials (DCTS) and patient centricity by design in rare disease studies (Life Sciences Review)

By Marcelo Vaz, Vice President of Medical Services at [...]

By TMC|2026-05-21T13:11:34+01:0027 May 2025|In the media|0 Comments

Navigating the complexity of compliance review of UK/EU product communications for rare diseases (Life Sciences Review)

By Marcelo Vaz, Vice President of Medical Services at [...]

By TMC|2026-05-21T13:11:39+01:0010 March 2025|In the media|0 Comments

TMC Pharma champions holistic approach to medical services in rare disease drug development (Samedan Pharmaceutical Publishers)
Gallery
TMC Pharma champions holistic approach to medical services in rare disease drug development (Samedan Pharmaceutical Publishers)

In the media

TMC Pharma champions holistic approach to medical services in rare disease drug development (Samedan Pharmaceutical Publishers)

By TMC|2026-05-21T13:14:21+01:0015 March 2024|In the media|0 Comments

Why rare disease day is so important (Samedan Pharmaceutical Publishers)
Gallery
Why rare disease day is so important (Samedan Pharmaceutical Publishers)

In the media

Why rare disease day is so important (Samedan Pharmaceutical Publishers)

By TMC|2026-05-21T13:14:17+01:006 March 2024|In the media|0 Comments